Currently, anti-TIM-3 drugs are being developed and are in clinical trials [1], since numerous preclinical studies show that TIM-3 expression on tumor cells leads to the development of resistance to anti-PD-1 or anti-CTLA-4 antibodies, and TIM-3 blocking induces an anti-tumor immune response [2,3,4,5]. Here, HAVCR2 is linked to neoplasm.